Clinical trials: Essential Hypertension.
Hypertension, Hypertension,Essential
The TARGET BP OFF-MED Trial
To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.
- Trial name
- NCT03503773
- Testing
- Alcohol
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 350 people
- Sponsor
- Ablative Solutions, Inc.
Hypertension
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.
- Trial name
- NCT00219154
- Testing
- aliskiren
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 1,125 people
- Sponsor
- Novartis
Hypertension, Essential
A Study to Evaluate the Efficacy and Safety of AD-209
The purpose of this study is to evaluate the efficacy and safety of AD-209
- Trial name
- NCT05631990
- Testing
- AD-209, AD-209-1A, AD-209-1B
- Where
- South Korea
- Volunteers
- 221 people
- Sponsor
- Addpharma Inc.
Essential Hypertension
Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension
The purpose of this study is to compare the safety and tolerability of azilsartan medoxomil plus chlorthalidone, once daily (QD), versus olmesartan medoxomil-hydrochlorothiazide in adults with essential hypertension.
- Trial name
- NCT00996281
- Testing
- Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil and hydrochlorothiazide
- Where
- 26 sites in Austria, Germany and 3 more
- Volunteers
- 837 people
- Sponsor
- Takeda
Hypertension,Essential
An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
The main purpose of this observation study is to collect data on the effects and side effects for 12 weeks of the medication administration of the single-pill combinations, which are fimasartan/amlodipine or…
- Trial name
- NCT05413057
- Where
- South Korea
- Volunteers
- 20,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients
The purpose of this study is to evaluate the antihypertensive efficacy and tolerability of 8 week treatment with Fimasartan (BR-A-657-K) 20, 60, 120, 240 mg and placebo in patients with mild to moderate essential hypertension and…
- Trial name
- NCT00923611
- Testing
- Fimasartan
- Where
- South Korea
- Volunteers
- 182 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch
The general aim of this trial to determine the efficacy as measured by the percentage of patients reaching blood pressure goal at the end of the treatment period at 12 weeks.
- Trial name
- NCT01134393
- Testing
- telmisartan/amlodipine
- Where
- 47 sites in Germany, Italy and 3 more
- Volunteers
- 502 people
- Sponsor
- Boehringer Ingelheim
Hypertension
A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)
This study will evaluate the safety and efficacy of long term treatment of SPP100 in patients with essential hypertension. (Trial is not recruiting in the US)
- Trial name
- NCT00246584
- Testing
- SPP100
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- Novartis
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"
The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1017-1" and co-administration of "BR1017-1A" and "BR1017-1B" in healthy volunteers
- Trial name
- NCT06184269
- Testing
- BR1017-1, BR1017-1A, BR1017-1B
- Where
- South Korea
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension
The purpose of this study is to compare the antihypertensive effect of chlorthalidone vs hydrochlorothiazide when each is used with azilsartan medoxomil, once daily (QD), in participants with moderate to severe essential…
- Trial name
- NCT00818883
- Testing
- Azilsartan medoxomil and chlorthalidone, Azilsartan medoxomil and hydrochlorothiazide
- Where
- 53 sites in United States, Russia
- Volunteers
- 609 people
- Sponsor
- Takeda
Hypertension, Essential Hypertension
Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of DWC202404 and DWC202314 Combination Therapy in Patients with Essential Hypertension Inadequately Controlled on DWC202404 Monotherapy
- Trial name
- NCT06682000
- Testing
- DWC202404, DWC202314, DWC202404, DWC202314P
- Where
- South Korea
- Volunteers
- 192 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypertension
One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.
- Trial name
- NCT00695955
- Testing
- Azilsartan medoxomil with or without add-on chlorthalidone, Azilsartan medoxomil with or without add-on hydrochlorothiazide
- Where
- 41 sites in United States, Chile and 1 more
- Volunteers
- 669 people
- Sponsor
- Takeda
Hypertension
Effectiveness of a Digital Health Application for Primary Hypertension (Liebria)
This clinical trial with 328 patients with primary hypertension aims to investigate the effectiveness of the self-guided digital application liebria for patients with primary hypertension.
- Trial name
- NCT06243978
- Testing
- liebria, information brochure on hypertension
- Where
- Germany
- Volunteers
- 328 people
- Sponsor
- Gaia AG
Essential Hypertension
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
This study will assess the efficacy and safety of the single pill combination of Aliskiren and Amlodipine in patients with moderate hypertension not adequately responding to a single pill combination of Olmesartan and Amlodipine.
- Trial name
- AWESOME (NCT01113047)
- Testing
- Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
- Where
- Germany
- Volunteers
- 347 people
- Sponsor
- Novartis
Primary Hypertension
A Study of LY2623091 in Participants With High Blood Pressure
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.
- Trial name
- NCT02194465
- Testing
- LY2623091, Tadalafil, Spironolactone
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Essential Hypertension
Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
The purpose of this study is to evaluate efficacy and safety of Irbesartan and Amlodipine combined therapy in patients with essential hypertension inadequately controlled on Irbesartan monotherapy
- Trial name
- NCT05475665
- Testing
- Irbesartan/Amlodipine, Irbesartan
- Where
- South Korea
- Volunteers
- 157 people
- Sponsor
- Handok Inc.
Hypertension
High Dose BAYA1040 CR: a Long Term Extension Study
This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040 CR 80 mg/day (40 mg twice daily) in patients with essential hypertension for whom the test drug is tolerable during the 8…
- Trial name
- NCT01355367
- Testing
- Nifedipine (Adalat, BAYA1040)
- Where
- 22 sites in Japan
- Volunteers
- 120 people
- Sponsor
- Bayer
Essential Hypertension
Monitoring the Effectiveness and Safety of Antihypertensive Therapy With a Fixed-Dose Combination of Perindopril and Amlodipine in Patients With Uncontrolled Essential Hypertension
The aim of this observational study is to monitor the effectiveness of therapy, adherence and safety of a fixed combination of perindopril + amlodipine in patients with essential hypertension.
- Trial name
- NCT07876895
- Testing
- fixed combination of perindopril + amlodipine
- Where
- Bosnia and Herzegovina
- Volunteers
- 600 people
- Sponsor
- Bosnalijek D.D
Hypertension
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (<140/90mmHg) at Baseline.
- Trial name
- NCT00624065
- Testing
- carvedilol controlled release/lisinopril
- Where
- 76 sites in United States
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Hypertension
Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension
The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil versus placebo in Korean adults with essential hypertension.
- Trial name
- NCT02203916
- Testing
- Azilsartan medoxomil
- Where
- 15 sites in South Korea
- Volunteers
- 328 people
- Sponsor
- Takeda